Panel 8 — Generics and the Patent Cliff

To help you get ready for the panel, here’s a list of questions to think about as you go through the book chapter and the Generic Drugs slides. There’s nothing to turn in — just look them over so you’re ready to join in. The questions I put to the panel come from this list.

From the reading

You can find these in the chapter and slides.

  1. What did the Hatch-Waxman Act (1984) change, and what is an Abbreviated New Drug Application (ANDA)?
  2. What does it mean for a generic to be “bioequivalent” to a brand-name drug?
  3. What typically happens to a drug’s price when generic competitors enter, and roughly by how much over time?
  4. What is a Paragraph IV certification, and what does a successful challenge earn the generic manufacturer?
  5. How do biologics and biosimilars differ from ordinary drugs and their generics?
  6. How can pharmacy benefit managers and large pharmacy chains blunt the price competition that generics are supposed to create?

Bigger questions

No single right answer here — these are the ones we’ll talk through together.

  1. The “patent cliff” — the sharp drop in a drug’s sales when its patent expires — is exactly what generic competition is meant to produce. Is that a feature or a problem, and for whom?
  2. Patents trade higher prices now for more new drugs later. Where would you set that balance?
  3. If generics are usually much cheaper, why do drug costs still feel so high to patients?
  4. Should a brand-name maker be allowed to sell its own “branded generic,” or does that undercut the point of generic competition?
  5. When a drug goes generic, who actually captures the savings — patients, insurers, PBMs, or pharmacies?

Your take

Have you or your family ever been offered a generic instead of a brand-name drug, or noticed the price of a medication change? What happened? Anything from your own experience is welcome.